Loading...
Two randomized trials showed that 5α-reductase inhibitors finasteride and dutasteride (Avodart) lowered risk for prostate cancer. However, in both trials (for unclear reasons), this drug class was associated with excess risk for high-grade (Gleason grade 8–10) prostate cancer (NEJM JW Gen Med Apr 16 2010), prompting an FDA warning. In this population-based, case-control study, investigators evaluated the association between prostate cancer and finasteride or dutasteride use in men with lower urinary tract symptoms caused by benign prostatic hyperplasia.
Twenty-seven thousand Swedish men with prostate cancer (cases) were matched with 134,000 controls; about 5% of men in each group had been exposed to 5α-reductase inhibitors. Multivariate anal…